TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00383188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
Study: NCT01076335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Hormonal Therapy
Description: Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
Study: NCT03987763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-122 Lotion
Description: Topical
Study: NCT04013698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP level 5 cmH2O
Description: PEEP level set for 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP level 5 cmH2O
Description: PEEP level set for 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP level 15 cmH2O
Description: PEEP level set for 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP level 15 cmH2O
Description: PEEP level set for 45 minutes
Study: NCT03573817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin
Description: Revefenacin is administered via a nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin
Description: Revefenacin is administered via a nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo version of Revefenacin is administered via a nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo version of Revefenacin is administered via a nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol
Description: Administered sequentially in both revefenacin and placebo arms using a nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Administered sequentially in both revefenacin and placebo arms using a nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol
Description: Administered sequentially in both revefenacin and placebo arms using a nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Administered sequentially in both revefenacin and placebo arms using a nebulizer.
Study: NCT02142231

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Acupuncture
Description: Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
Study: NCT02379234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation
Description: Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
Study: NCT01830361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin (PKC412)
Description: Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
Study: NCT01574222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell adenovirus CCL21 vaccine
Description: Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
Study: NCT04202562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ab interno trabeculectomy
Description: Ab interno trabeculectomy performed after pupil contraction and 90 degrees ablation of the nasal trabecular meshwork

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract
Description: Cataract surgery with minimal clear cornea incision and phacoemulsification

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract
Description: Cataract surgery with minimal clear cornea incision and phacoemulsification
Study: NCT04182620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: renal denervation
Description: Renal denervation using the Paradise renal denervation system - a dedicated RDN catheter that delivers a circumferential ring of ablative ultrasound energy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation
Study: NCT01598857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blisibimod

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02038296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization
Study: NCT04442958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convalescent Immune Plasma
Description: One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
Study: NCT01630109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule made to look like the metoclopramide capsule.
Study: NCT02778516

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Restriction

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Restriction
Study: NCT02491073

Intervention type: OTHER
Intervention: blood draw
Description: Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.

Intervention type: OTHER
Intervention: blood draw
Description: Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
Study: NCT06222372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: antibiotic
Study: NCT01152333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-(9-39) Acetate
Description: Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
Study: NCT02739022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Psychological Support for the Critically Ill (EPSCI)
Description: early psychological support based on positive therapeutic suggestion
Study: NCT03454347

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Profile Perform
Description: The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Limb Suspension
Description: This group will complete two weeks of lower limb suspension.
Study: NCT03388827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laminaria tent
Description: Laminaria tent was inserted for 12 hours before Hysteroscopy
Study: NCT02524652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% 20 mLs
Description: Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 20 mLs
Description: Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
Study: NCT05281783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous radiofrequency ablation (RFA)
Description: We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
Study: NCT04436822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: CGM and frequent sample testing
Study: NCT02713230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine liposome injectable suspension
Description: 10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine liposome injectable suspension
Description: 20 mL EXPAREL (bupivacaine liposome injectable suspension)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL normal saline as single-injection
Study: NCT03388827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria plus Misoprostol
Description: Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
Study: NCT02753972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating and Living
Description: 8 week mindfulness skills intervention
Study: NCT01419665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP2013
Description: Type: Biological/Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Type: Biological/Vaccine
Study: NCT02065947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: catheter with 3-level-injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl, propofol, atracurium
Description: endotracheal intubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine , adrenaline, ketamine bolus, midazolam
Description: a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter with 3-level-injection
Study: NCT02753972

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Weight Loss Control
Description: 8 week active weight loss control group
Study: NCT03439488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-440
Description: JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-440
Description: JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-440
Description: JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
Study: NCT01661673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-0962
Description: Arms: 1,2,3,4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-0962
Description: Arms: 1,2,3,4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-0962
Description: Arms: 1,2,3,4
Study: NCT02065947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane and 50% oxygen in air
Study: NCT01661673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-0962
Description: Arms: 1,2,3,4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 5
Study: NCT00246103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Beginning Dose, Level 1: 15 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Beginning Dose, Level 1: 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide.
Description: For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m\^2.
Study: NCT03926013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63898081
Description: JNJ-63898081 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63898081
Description: JNJ-63898081 will be administered.
Study: NCT01678742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-protein diet
Description: The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet
Description: The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
Study: NCT04236076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseHaler
Description: PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham - control
Description: Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
Study: NCT05585294

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
Study: NCT05053685

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Urine and plasma metanephrines
Description: Measurement of Urine and plasma metanephrines

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Urine and plasma metanephrines
Description: Measurement of Urine and plasma metanephrines
Study: NCT02729415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stromal Vascular Fraction Cells (SVF Cells) Injection
Description: The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair Measurements
Description: Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
Study: NCT00375713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: 1 Levocetirizine 5mg tablet per day before bedtime for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: 1 Cetirizine 10mg tablet per day before bedtime for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Levocetirizine
Description: 1 Placebo-Levocetirizine tablet per day before bedtime for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Cetirizine
Description: 1 Placebo-Cetirizine tablet per day before bedtime for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard topical steroid (1% hydrocortisone) ointment
Description: 1% hydrocortisone ointment, applied 2-3 times a day to all affected areas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard topical steroid (1% hydrocortisone) ointment
Description: 1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
Study: NCT02749916

Intervention type: OTHER
Intervention: Methods of carotid wall imaging
Study: NCT01139515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan commercial tablet
Description: 20 mg tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan commercial tablet
Description: 40 mg tablet, single dose of 1 X 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan commercial tablet
Description: 40 mg tablet, single dose of 2 X 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan commercial tablet
Description: 40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
Study: NCT00095576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10\^10 adenovirus genomes \[ad-vg\]/dose).~This dose is equivalent to 3x10\^10 vp/dose used in study V520-016.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
Study: NCT04448379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: IV infusion Q2W for 4 weeks (28-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: IV infusion Q2W for 4 weeks (28-day cycles)
Study: NCT01512576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: 1 treatment session of 30 minutes
Study: NCT03999476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambu ascope
Description: nasal route intubation by the device in fixed cancer tongue patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fibreroptic bronchoscope
Description: nasal route intubation by the device in fixed cancer tongue patients
Study: NCT02692534

Intervention type: OTHER
Intervention: Urine cocaine negative
Description: Preoperative urine cocaine negative

Intervention type: OTHER
Intervention: Urine cocaine positive
Description: Preoperative urine cocaine positive
Study: NCT04765397

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effect of different resectoscope fluids on optic nerve diameter measured by ultrasound
Description: During the operation Blood pressure, pulse minute the number of irrigation solutions used, and intravenous serum amounts, operation time will be saved. If there is an abnormal parameters or increased optic nerve sheath surgical team will be informed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effect of different resectoscope fluids on optic nerve diameter measured by ultrasound
Description: During the operation Blood pressure, pulse minute the number of irrigation solutions used, and intravenous serum amounts, operation time will be saved. If there is an abnormal parameters or increased optic nerve sheath surgical team will be informed.